UroGen Pharma Ltd. - Ordinary Shares (URGN) News
Filter URGN News Items
URGN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
URGN News Highlights
- URGN's 30 day story count now stands at 9.
- Over the past 27 days, the trend for URGN's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about URGN are BEAT and GEL.
Latest URGN News From Around the Web
Below are the latest news stories about UROGEN PHARMA LTD that investors may wish to consider to help them evaluate URGN as an investment opportunity.
With 58% institutional ownership, UroGen Pharma Ltd. (NASDAQ:URGN) is a favorite amongst the big gunsKey Insights Institutions' substantial holdings in UroGen Pharma implies that they have significant influence over the... |
UroGen Pharma Ltd. (NASDAQ:URGN) Q1 2023 Earnings Call TranscriptUroGen Pharma Ltd. (NASDAQ:URGN) Q1 2023 Earnings Call Transcript May 11, 2023 UroGen Pharma Ltd. beats earnings expectations. Reported EPS is $-1.3, expectations were $-1.33. Operator: Good morning, ladies and gentlemen. Thank you for standing by, and welcome to the UroGen Pharma Q1 2023 Earnings Call. Please be advised that today’s conference is being recorded. […] |
Urogen Pharma (URGN) Reports Q1 Loss, Tops Revenue EstimatesUrogen Pharma (URGN) delivered earnings and revenue surprises of 6.47% and 3.88%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock? |
UroGen Pharma Meets Revenue Goal, Reports First Quarter 2023 Financial Results and Recent Corporate DevelopmentsPRINCETON, N.J., May 11, 2023--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced financial results for the first quarter ended March 31, 2023, and provided an overview of recent developments. |
UroGen Pharma to Report 2023 First Quarter Financial Results on Thursday, May 11, 2023PRINCETON, N.J., May 04, 2023--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will report 2023 first quarter financial results on Thursday, May 11, 2023, prior to the open of the stock market. The announcement will be followed by a live audio webcast and conference call at 10:00 AM Eastern Time. |
Earnings Preview: Urogen Pharma (URGN) Q1 Earnings Expected to DeclineUrogen Pharma (URGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
First Study to Evaluate JELMYTO® Use Post-Complete Endoscopic Ablation Reports 69% of Patients were Disease Free at the Time of First Endoscopic EvaluationPRINCETON, N.J., May 01, 2023--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today highlights the results of a sub-analysis from the first and largest post-commercial utilization review of JELMYTO (mitomycin) for pyelocalyceal solution presented today at the American Urological Association Meeting 2023 in Chicago, IL. The study titled, "Efficacy and Safety of Mitomycin Gel (UGN-10 |
New Retrospective Study Presented at AUA 2023 Provides Evidence of Similar Outcomes Utilizing JELMYTO® in the Treatment of UTUC of the Ureter and Renal PelvisPRINCTON, N.J., April 30, 2023--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today highlights the results of a sub-analysis from the first and largest post-commercial utilization review of JELMYTO® (mitomycin) for pyelocalyceal solution presented at the American Urological Association Meeting 2023 in Chicago, IL. The study titled, First Analysis of the Safety and Efficacy of UGN- |
UroGen Pharma to Present at H.C. Wainwright BioConnect ConferencePRINCETON, N.J., April 25, 2023--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will participate in a fireside chat at the upcoming H.C. Wainwright BioConnect Conference on May 2, 2023 at 10:00 AM ET. |
UroGen Pharma Ltd.'s (NASDAQ:URGN) Prospects Need A Boost To Lift SharesWith a price-to-sales (or "P/S") ratio of 3.5x UroGen Pharma Ltd. ( NASDAQ:URGN ) may be sending very bullish signals... |